Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents
Inflammatory Bowel Diseases2012Vol. 18(11), pp. 2011–2017
Citations Over TimeTop 10% of 2012 papers
Pauliina Molander, Clas-Göran af Björkesten, Harri Mustonen, Johanna Haapamäki, Matti Vauhkonen, Kaija‐Leena Kolho, Martti Färkkilâ, Taina Sipponen
Abstract
A normal FC after induction therapy with TNFα antagonists predicts sustained clinical remission in the majority of patients on scheduled therapy with active luminal disease.
Related Papers
- → Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis(2008)377 cited
- → Effectiveness of infliximab after adalimumab failure in Crohn's disease.(2012)32 cited
- Effectiveness of infliximab after adalimumab failure in Crohn＇s disease(2012)
- → Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease(2013)17 cited
- → SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB(2017)14 cited